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BACKGROUND: Lone atrial fibrillation (AF) may reflect a subclinical 
cardiomyopathy that persists after sinus rhythm (SR) restoration, providing a 
substrate for AF recurrence. To test this hypothesis, we investigated the effect of 
restoring SR by catheter ablation on left ventricular (LV) function and energetics in 
patients with AF but no significant comorbidities.
METHODS: Fifty-three patients with symptomatic paroxysmal or persistent AF and 
without significant valvular disease, uncontrolled hypertension, coronary artery disease, 
uncontrolled thyroid disease, systemic inflammatory disease, diabetes mellitus, or 
obstructive sleep apnea (ie, lone AF) undergoing ablation and 25 matched control 
subjects in SR were investigated. Magnetic resonance imaging quantified LV ejection 
fraction (LVEF), peak systolic circumferential strain (PSCS), and left atrial volumes 
and function, whereas phosphorus-31 magnetic resonance spectroscopy evaluated 
ventricular energetics (ratio of phosphocreatine to ATP). AF burden was determined 
before and after ablation by 7-day Holter monitoring; intermittent ECG event monitoring 
was also undertaken after ablation to investigate for asymptomatic AF recurrence.
RESULTS: Before ablation, both LV function and energetics were significantly 
impaired in patients compared with control subjects (LVEF, 61% [interquartile range 
(IQR), 52%–65%] versus 71% [IQR, 69%–73%], P<0.001; PSCS, –15% [IQR, –11 to 
–18%] versus −18% [IQR, –17% to –19%], P=0.002; ratio of phosphocreatine to ATP, 
1.81±0.35 versus 2.05±0.29, P=0.004). As expected, patients also had dilated and 
impaired left atria compared with control subjects (all P<0.001). Early after ablation 
(1–4 days), LVEF and PSCS improved in patients recovering SR from AF (LVEF, 
7.0±10%, P=0.005; PSCS, –3.5±4.3%, P=0.001) but were unchanged in those in 
SR during both assessments (both P=NS). At 6 to 9 months after ablation, AF burden 
reduced significantly (from 54% [IQR, 1.5%–100%] to 0% [IQR 0%–0.1%]; P<0.001). 
However, LVEF and PSCS did not improve further (both P=NS) and remained impaired 
compared with control subjects (P<0.001 and P=0.003, respectively). Similarly, there 
was no significant improvement in atrial function from before ablation (P=NS), and 
this remained lower than in control subjects (P<0.001). The ratio of phosphocreatine 
to ATP was unaffected by heart rhythm during assessment and AF burden before 
ablation (both P=NS). It was unchanged after ablation (P=0.57), remaining lower than 
in control subjects regardless of both recovery of SR and freedom from recurrent AF 
(P=0.006 and P=0.002, respectively).
CONCLUSIONS: Patients with lone AF have impaired myocardial energetics and 
subtle LV dysfunction, which do not normalize after ablation. These findings suggest 
that AF may be the consequence (rather than the cause) of an occult cardiomyopathy, 
which persists despite a significant reduction in AF burden after ablation.
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atrial fibrillation (AF), the most common sustained clinical arrhythmia, is associated with an increased risk of severe stroke,1 myocardial infarction,2 and 
premature death.3 The worldwide incidence, prevalence, 
and age-adjusted mortality from AF are increasing, pre-
senting a rapidly growing public health and economic 
burden.4
Mechanistic studies in animal models of pacing-
induced AF indicate that atrial remodeling,5 oxidative 
stress,6 and impaired coronary reserve7 induced by 
AF are important in arrhythmia maintenance. Howev-
er, direct translation of these findings is challenging 
because human AF often reflects multiple interacting 
causative factors. Indeed, no unique mechanisms for 
AF have been identified in patients,8 even in the up to 
one third of cases in which AF occurs in the absence of 
identifiable underlying cardiovascular disease or other 
specific cause9 (conventionally referred to as lone AF, 
although the use of this term has recently been ques-
tioned10).
Subtle left ventricular (LV) dysfunction has been ob-
served in patients with AF,11 with several studies show-
ing that adverse LV structural remodeling and dysfunc-
tion are at least partially reversible after restoration of 
sinus rhythm (SR) with catheter ablation.12 Even when 
the ventricular rate is well controlled, AF may lead to LV 
dysfunction by reducing myocardial perfusion reserve, 
impairing calcium handling, and increasing myocardial 
oxidative stress and fibrosis.13 However, large-scale 
clinical trials of pharmacological strategies designed 
to restore SR have failed to show prognostic benefit 
(eg, reduction in death, stroke, or heart failure hospi-
talizations) compared with ventricular rate control,14–16 
whereas the effect of catheter ablation remains to be 
investigated. These results could reflect limited efficacy 
and potential toxicity of antiarrhythmic medications; nev-
ertheless, it remains the case that at present there are 
no randomized, clinical data demonstrating that restora-
tion of SR improves major outcomes in patients with AF, 
raising the possibility that, at least in patients with lone 
AF and controlled ventricular rate, the arrhythmia may 
not be the primary cause of LV dysfunction. Instead, a 
subclinical cardiomyopathy that persists after restora-
tion of SR may provide a substrate for AF initiation and 
recurrence and an effect on patient prognosis. Here, we 
used cardiac magnetic resonance (MR) to serially as-
sess atrial and LV volumes and function in patients with 
AF before and after catheter ablation. We included both 
early and late postablation MR assessments to quantify 
the proportion of any improvement in LV function result-
ing from short-term changes in hemodynamics versus 
longer-term beneficial cardiac remodeling. We also 
used phosphorus-31 MR spectroscopy (31P-MRS) to de-
termine myocardial energetics before and after ablation 
because altered cardiac energy metabolism has been 
identified as an early marker of cardiomyopathy.17
MethODs
This prospective study was undertaken in a single tertiary 
center. The study protocol was approved by a local Research 
Ethics Committee, and all subjects gave written informed 
consent.
Patient Population
Patients undergoing first-time catheter ablation of symptom-
atic paroxysmal or persistent AF were screened for eligibility. 
Individuals with significant valvular disease, uncontrolled arte-
rial hypertension, known coronary artery disease, uncontrolled 
thyroid disease, systemic inflammatory disease, asthma, dia-
betes mellitus, or obstructive sleep apnea were not enrolled. 
Further exclusion criteria were contraindications to cardiac MR 
(including implanted metallic devices and claustrophobia) or 
gadolinium administration (estimated glomerular filtration rate 
<30 mL/min).
Clinical management of patients (including ablation strategy 
and choice of anticoagulant and antiarrhythmic drugs) was at 
the discretion of the responsible physician.
clinical Perspective
What is new?
•	Patients with apparently lone atrial fibrillation (AF) 
have significantly impaired ventricular myocardial 
energetics, a characteristic and early feature of 
cardiomyopathy, as well as reduced left ventricular 
ejection fraction and abnormal peak systolic circum-
ferential strain.
•	After catheter ablation, left ventricular function 
improves rapidly (driven by a switch to sinus rhythm 
at the time of imaging); however, left ventricular func-
tion remains abnormal at 6 to 9 months after abla-
tion (despite a significant reduction in AF burden).
•	Myocardial energetics are completely unchanged 
after ablation, even in patients with substantial and 
sustained reduction in AF burden.
What are the clinical implications?
•	Our results suggest that apparently lone AF may 
actually be the consequence (rather than the cause) 
of an occult cardiomyopathy that is unaffected by 
ablation.
•	 Improvement in left ventricular ejection fraction after 
ablation does not necessarily indicate beneficial car-
diac remodeling induced by sinus rhythm; caution 
may be needed in interpreting improvement in ejec-
tion fraction as a biomarker of possible prognostic 
benefit from ablation.
•	 Future studies are needed to examine whether 
therapeutic strategies that target the adverse car-
diometabolic phenotype could reduce AF recurrence 
and improve outcomes.
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control group
Control subjects in SR were recruited via poster advertising. 
Exclusion criteria were identical to those for patients, except 
that volunteers with a history of palpitations or arrhythmia were 
not enrolled. Control subjects were selected to match patients 
for age and sex.
study Protocol
Patients were studied at 3 time points: up to 4 weeks before 
ablation, early after ablation (up to 4 days from the procedure), 
and at later follow-up (between 6 and 9 months after ablation). 
Myocardial energetics was not assessed at the early postabla-
tion time point. Control subjects were studied at a single time 
point.
Definitions of paroxysmal and persistent AF were based 
on contemporary clinical guidelines.18 AF burden in patients 
with paroxysmal AF was assessed before ablation with a 7-day 
Holter monitor. After ablation, all patients underwent inter-
mittent ECG event monitoring for ≈3 months after an initial 
3-month blanking period. Seven-day Holter monitoring was 
also undertaken after the last follow-up visit. Because the pur-
pose of these investigations was to investigate asymptomatic 
recurrence of AF and AF burden, they were not undertaken 
in patients with ECG-documented recurrence of persistent AF. 
Patients with a history of persistent AF who had undergone 
cardioversion to SR before ablation (n=3) were excluded from 
the calculation of change in AF burden postablation.
Patients were classified on the basis of both rhythm during 
each study assessment and the presence or absence of recur-
rent AF after the procedure. For the former, patients were 
categorized by rhythm at the visit ≤4 weeks before ablation 
and at both follow-up visits. For example, a patient in AF ≤4 
weeks before ablation who had recovered SR early after abla-
tion but relapsed to AF by the last follow-up visit was classified 
as AF-SR at the early time point and AF-AF at the last follow-
up. Patients with at least 1 of the following were classified as 
having recurrent postprocedural AF: ECG-documented clinical 
recurrence after the blanking period, ≥30 seconds19 of AF or 
other atrial arrhythmia (eg, atrial flutter or focal atrial tachycar-
dia) on postablation Holter monitoring, or ≥1 rhythm strip (30 
seconds) showing AF or other atrial arrhythmia on intermittent 
ECG monitoring.
Patients who consented to the study but did not contribute 
any imaging data (because of claustrophobia [n=2], inability to 
tolerate MR [n=2], or cancellation of the planned ablation [n=1]) 
are not included in the tables of demographic information.
cardiac Mr Protocol and analysis
MR imaging was performed at 1.5 T (Siemens Avanto, 
Siemens Healthcare, Erlangen, Germany) or 3 T (TIM Trio, 
Siemens Healthcare) with a 32-channel phased-array coil 
with the subject supine. Images were acquired during end 
expiration to minimize the effects of respiratory motion. 
Pulse sequence parameters and details of the analysis 
method are provided in the Methods in the online-only Data 
Supplement.
Cines were acquired with retrospective gating for patients 
in SR at the time of the scan and with arrhythmia sorting as 
a first-choice method for patients in AF at the time of the 
scan. For the minority of patients in AF in whom acceptable 
images could not be obtained, prospectively triggered cines 
were acquired instead. Real-time acquisition sequences were 
also undertaken for all patients in AF during scanning to allow 
visual assessment of ejection fraction (EF) and corroborate 
quantitative volumetric analysis. No cases were identified with 
discordance between visual assessment of EF on real-time 
acquisition and the results of blinded quantitative volumetric 
analysis.
Cine image analysis was conducted offline with cmr42 
postprocessing software (version 5.1.1, Circle Cardiovascular 
Imaging Inc, Calgary, ON, Canada). All data sets were anony-
mized and placed in a random order for contouring. Contours 
were placed by an operator not involved with data acquisition 
who was blinded to clinical status, study time point, and rhythm 
at the time of scanning. Because MR cine loops reconstruct 
a single R-R interval, R-R variability is not apparent on view-
ing the cine, and it is possible to be blinded to the presence 
of AF (Movie I in the online-only Data Supplement). Left atrial 
maximal volume (LAmax) and minimal volume (LAmin) were deter-
mined with the biplane area-length method, as previously 
described,20 and used to calculate total left atrial emptying 
fraction: LAEF=(LAmax−LAmin)/LAmax.
Strain imaging was performed with a prospectively trig-
gered myocardial tagging sequence, as described previously.21
Postprocessing of tagging images was performed with 
CIM-Tag software (Auckland, New Zealand). Semiautomated 
analysis was performed by aligning a grid to the myocardial 
tagging planes in end diastole. End systole was determined 
visually, and tags were adjusted at each frame through the 
cardiac cycle to derive peak systolic circumferential strain 
(PSCS) for the midventricular slice, which is expressed as a 
percentage change from end diastole. Normal PSCS has been 
described22 as –19±2%; impaired myocardial contractility is 
shown by a more positive value.
Late gadolinium enhancement (LGE) imaging was acquired 
in 3 short-axis planes (basal, midventricular, and apical) at ≈8 
to 10 minutes after intravenous administration of MR contrast 
agent (total, 0.13 mmol/kg body weight of gadolinium-DTPA; 
Dotarem, Guerbet, France). The inversion time was adjusted 
for optimal nulling of remote normal myocardium. Images were 
assessed by 2 experienced operators at the time of acquisi-
tion, and LGE suspected on short-axis imaging was confirmed 
with additional long-axis imaging. Quantitative analysis was 
undertaken with cmr42 postprocessing software (as above) on 
midventricular slices matching the sites of acquisition of 31P-
MRS data, by setting a signal intensity threshold at 5 SD above 
the mean intensity of a reference region of interest placed 
in a remote area of myocardium with no visual evidence of 
enhancement.
31P-Mrs Protocol and analysis
31P-MRS was performed at 3 T (TIM Trio, Siemens Healthcare) 
to obtain the ratio of phosphocreatine to ATP concentration 
(PCr/ATP) from a voxel in the midventricular septum. Subjects 
fasted overnight and were placed prone with their heart over 
the center of the 31P heart/liver coil, as described previ-
ously.23,24 Acquisition time was ≈9 minutes in a non–ECG-gated 
acquisition. Postprocessing was performed as previously 
described.25
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echocardiography
Transthoracic echocardiography was undertaken in the left 
lateral position to determine the ratio of peak early diastolic 
mitral inflow velocity to spectral tissue Doppler-derived peak 
early diastolic velocity at the mitral annulus (E/E’) as a marker 
of LV diastolic function.26 These measures were averaged over 
at least 10 cardiac cycles for patients in AF during imaging. 
E/E’ values reported are the average of lateral and septal 
measurements.
statistical analysis
A priori sample size calculation was performed to detect a 
change in the primary outcome of LVEF after ablation. On the 
basis of the assumption that patients with AF have an LVEF of 
55±10%, we calculated that paired analysis of 45 patients 
before and after ablation would give >90% power to detect 
a change in LVEF of at least 5 percentage points (2-sided 
α=0.05). This number of patients would also allow detection 
of a change in PCr/ATP ratio after ablation of ≥10% with >90% 
power (2-sided α=0.05). We recruited ≈60 patients to allow 
for incomplete follow-up, claustrophobia, and other obstacles 
to completing the protocol. On the basis of pilot data indicat-
ing that the PCr/ATP ratio was 1.84±0.41 in patients with 
AF (n=10) and 2.12±0.26 in normal subjects (n=8), we cal-
culated that recruitment of ≥20 control subjects and ≥40 
patients with AF (1:2 allocation) would give >90% power to 
detect a 13% reduction in PCr/ATP ratio in patients compared 
with control subjects.
Statistical analyses were performed with IBM SPSS 
Statistics for Windows, version 20.0 (IBM Corp, Armonk, NY), 
GraphPad Prism version 6 (GraphPad Software, San Diego, 
CA), and G*Power version 3.1.9.2.27 Normality of data was 
assessed with Kolmogorov-Smirnov tests. Normally distrib-
uted data were compared by use of t tests (paired when 
appropriate) and 1-way ANOVA. Nonnormally distributed 
unpaired data were compared by use of the Mann-Whitney 
U test or the Kruskal-Wallis test, and nonnormally distributed 
paired data were compared with the Wilcoxon signed-rank 
test or the related-samples Friedman 2-way ANOVA by ranks. 
The χ2 test was used to compare proportions. All tests were 
2 tailed, and values of P<0.05 (after Bonferroni or equiva-
lent adjustment for multiple comparisons when appropriate) 
were considered significant. Data are shown as mean±SD or 
median and interquartile range (IQR).
results
A total of 58 patients with AF consented to the study; 
53 provided at least 1 set of imaging data, and 45 com-
pleted all 3 study visits (Figure 1). The early follow-up 
visit was conducted at a median of 20 hours after abla-
tion (IQR, 19–23 hours) and the late follow-up visit at a 
median of 7 months (IQR, 7–9 months).
Baseline characteristics of patients and control sub-
jects, medications, and procedural details of ablation 
categorized by AF type are summarized in Table 1 and 
online-only Data Supplement Table I. Median time from 
the first diagnosis was 3.7 years (IQR, 2.0–7.3 years). 
Patients with persistent AF had slightly higher body 
mass index and resting pulse than patients with par-
oxysmal AF, but exclusion of patients with uncontrolled 
ventricular rate meant that the resting pulse rate was 
well controlled in the persistent AF group (median, 72 
bpm; IQR, 65–90 bpm). Median AF burden in patients 
with paroxysmal AF before ablation was 2.6% (≈4.5 h/
wk), whereas median AF burden in all patients was 54% 
(≈91 h/wk).
Figure 1. Flowchart of patients with atrial fibrillation 
through the study.  
The number of patients consenting to the study, completing 
the preablation (PRE) visit, undergoing ablation, and complet-
ing the early (20H) and late (7M) visits is shown. The number 
of patients not completing each stage is also indicated, with 
reasons given. MRI indicates magnetic resonance imaging.
table 1. Baseline characteristics of the study 
groups
 
Patients With 
aF (n=53)
control 
subjects in sr 
(n=25) P Value
Age, y 63±8 61±6 0.294
Male, % 75 72 0.743
BMI, kg/m2 27 (24–31) 26 (24–29) 0.277
Resting pulse, bpm 64 (54–80) 60 (60–66) 0.620
SBP, mm Hg 130 (124–145) 126 (119–139) 0.124
DBP, mm Hg 81±11 78±10 0.257
Ever smoked, % 38 20 0.117
Alcohol, units/wk 9 (1–20) 6 (0–19) 0.690
AF indicates atrial fibrillation; BMI, body mass index; DBP, diastolic blood 
pressure; SBP, systolic blood pressure; and SR, sinus rhythm.
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results in control subjects and Patients With aF 
Before ablation
LV volume, function, and mass indexes and left atrial 
volumes and function in control subjects and preabla-
tion patients are summarized in Table 2. There were no 
significant differences in LV end-diastolic volumes be-
tween the groups, but patients with AF had significantly 
larger end-systolic volumes and hence lower LVEF than 
matched control subjects (both P<0.001). However, the 
impairment in LVEF was subtle, and the median LVEF in 
patients (61%) fell at the lower end of the normal range 
by MR imaging in our institution (57%–81%).28 PSCS 
was more clearly abnormal in patients with AF (median, 
–15% [IQR, –11% to –18%]; normal, –19±2%22) and was 
significantly impaired compared with control subjects 
(Table 2). As expected, patients with AF had dilated and 
impaired left atria compared with control subjects (all 
P<0.001; Table 2).
Consistent with our exclusion of patients with un-
controlled hypertension, LV mass index (by MR) and 
LV diastolic function (by echocardiography) were within 
the normal range in both patients and control subjects 
(Table 2). The ratio of LV mass to LV end-diastolic vol-
ume (which identifies the presence of concentric LV re-
modeling in the absence of an absolute increase in LV 
mass29) was also similar between patients and control 
subjects and was consistent with data reported from 
healthy control subjects of a similar age in a previous 
MR study.30
The quality of 31P-MRS data was equally good in pa-
tients and control subjects (median Cramér-Rao lower 
bounds31 coefficient of variation of PCr/ATP, 15% for 
patients and 14% for control subjects; P=0.52; repre-
sentative spectra are shown in Figure 2A). Myocardial 
energetics was significantly impaired in patients with AF 
compared with control subjects (PCr/ATP, 1.81±0.35 
versus 2.05±0.29; P=0.004; Figure 2B). Energetics 
was similarly impaired regardless of the preablation in-
trascan rhythm and regardless of Holter-determined AF 
burden for those in SR (PCr/ATP, 1.80±0.39 for preab-
lation AF, 1.86±0.35 for preablation SR with higher-
than-median AF burden, and 1.77±0.32 for preabla-
tion SR with lower-than-median AF burden; P=0.84; 
Figure 3A). In contrast, presence of AF (rather than 
SR) during the preablation scan was associated with a 
significantly lower LVEF (median, 54% [IQR, 48%–60%] 
versus median 64% [IQR, 63%–69%]; P<0.001), but 
there was no difference in LVEF between patients in SR 
with higher and those with lower AF burden (P=0.34; 
Figure 3B).
LGE, indicating LV fibrosis or scar, was an infre-
quent finding that was detected in 8 patients (15%) 
and 2 control subjects (8%). In 5 patients, LGE had a 
localized subendocardial or transmural pattern consis-
tent with a small infarct (which had not been identified 
on echocardiography); 4 of these patients had no ob-
structive coronary artery disease at angiography, and 
the cause of infarction was presumed to be embolic. 
The other 3 patients and both control subjects had 
a nonischemic pattern of diffuse or patchy fibrosis. 
No subject had LGE affecting the midventricular sep-
tum (ie, the site of sampling for 31P-MRS). When the 
subjects with LGE were removed from the analysis, 
table 2. lV and left atrial indexes in the study groups
 Patients With aF (n=53) control subjects in sr (n=25) P Value
LV end-diastolic volume, mL 149±39 137±30 0.189
LV end-systolic volume, mL 58 (43 to 75) 41 (33 to 51) <0.001*
LV stroke volume, mL 81 (71 to 94) 93 (83 to 109) 0.035*
LVEF, % 61 (52 to 65) 71 (69 to 73) <0.001*
Cardiac output, L/min 5.6±1.5 6.0±1.4 0.326
LV mass index, g/m2 61±12 56±13 0.112
LV mass/end-diastolic volume, g/mL 0.85 (0.73 to 0.96) 0.77 (0.73 to 0.86) 0.181
Peak systolic circumferential strain, % –15 (–11 to –18) −18 (–17 to –19) 0.002*
LV E/E’ ratio 7.0 (5.8 to 8.7) 7.6 (6.3 to 8.6) 0.304
LV LGE area, % 0.2 (0 to 0.5) 0.1 (0 to 0.3) 0.190
LA
max
, mL 102±35 77±22 <0.001*
LA
min
, mL 71±36 35±11 <0.001*
LAEF, % 30 (16 to 49) 53 (49 to 61) <0.001*
AF indicates atrial fibrillation; E/E’ ratio, ratio of peak early diastolic mitral inflow velocity to spectral tissue Doppler-derived peak early 
diastolic velocity at the mitral annulus; LAEF, left atrial total emptying fraction; LA
max
, left atrial maximal volume; LA
min
, left atrial minimal 
volume; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; and SR, sinus rhythm. 
* Significant.
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PCr/ATP and LVEF in patients with AF remained signifi-
cantly impaired compared with control subjects in SR 
(PCr/ATP, 1.81±0.37 in the 45 remaining patients ver-
sus 2.01±0.26 in the 23 remaining control subjects, 
P=0.02; median LVEF, 61% [IQR, 52%–65%] in the 45 
remaining patients versus median 71% [IQR, 69%–
73%] in the 23 remaining control subjects, P<0.001). 
Quantitative analysis of LGE demonstrated no differ-
ence in the area of enhancement between patients 
and control subjects (median, 0.2% [IQR, 0%–0.5%] in 
patients versus 0.1% [IQR, 0%–0.3%] in control subjects; 
P=0.19). No new areas of LGE were noted at the posta-
blation scans.
Outcomes after ablation
Ablation was undertaken in 51 patients, with no signifi-
cant early procedural complications. Radiofrequency 
ablation was used in 35 patients (69%), cryoballoon ab-
lation in 14 patients (27%), and laser balloon ablation 
in 2 patients (4%). In the time span between the end 
of the 3-month blanking period and the 7-month visit, 9 
patients (18%) underwent an attempt at electric cardio-
version and 3 patients (6%) underwent a second ablation 
procedure as a result of recurrence of AF or focal left 
atrial tachycardia.
At 20 hours, the classification of patients by 
rhythm groups was as follows: SR-SR, 24; AF-SR, 21; 
and AF-AF, 3. At 7 months, the numbers were the fol-
lowing: SR-SR, 21; AF-SR, 19; AF-AF, 4; and SR-AF, 
2. Of 46 patients scanned at 7 months, 25 (54%) 
had evidence of ≥1 episodes of recurrent AF after 
ablation. However, Holter-determined AF burden at 
7 months was significantly lower than before abla-
tion (median, 0% [IQR, 0%–0.1%] versus 54% [IQR, 
1.5%–100%]; P<0.001).
early effect of ablation on lV Function
Early after ablation, there was no significant overall 
change in LVEF (median, 61% [IQR 51%–65%] ≤4 weeks 
before ablation versus 61% [IQR, 57%–66%] at 20 
hours; n=48; P=0.07). However, there was a significant 
increase in LVEF (7.0±10%) in the AF-SR subgroup, un-
like the SR-SR and AF-AF subgroups, in which LVEF was 
unchanged (Figure 4A). A similar pattern was seen for 
PSCS, with a significant change of –3.5±4.3% (indicat-
ing improvement) in the AF-SR subgroup but no change 
in the other subgroups (Figure 4B).
The SR-SR subgroup showed a significant increase in 
heart rate from ≤4 weeks before ablation to 20 hours 
(Figure 4C), consistent with the expected inflammation32 
and increase in sympathetic activity33 induced by the 
procedure; this effect was entirely counteracted in the 
AF-SR subgroup by the reduction in ventricular rate as-
sociated with recovery of SR.
Figure 2. representative phosphorus-31 magnetic resonance (31P-Mr) spectra and myocardial energetics in 
the study groups.  
A, Images (left) show a midventricular short-axis slice, with the selected voxel positioned on the septum and highlighted (red 
rectangle). Saturation band positions are also shown (yellow). Spectra (right) show both raw data (black) and fitted line (red); 
peaks are labeled corresponding to 2,3-diphosphoglycerate (2,3-DPG), phosphodiester (PDE), phosphocreatine (PCr), and γ, α, 
and β peaks of ATP. Representative 31P-MR spectra from a control subject in SR with a PCr/ATP ratio of 2.08 and a patient with 
AF before ablation with a PCr/ATP ratio of 1.74. B, PCr/ATP ratio in control subjects and patients (n=25 and n=52, respectively; 
P=0.004 by unpaired t test).
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Overall, cardiac output increased significantly after 
ablation (6.6±1.6 L/min at 20 hours compared with 
5.6±1.5 L/min ≤4 weeks before ablation; P<0.001), driv-
en by both the AF-SR and SR-SR subgroups (Figure 4D).
late effect of ablation on lV Function, 
Myocardial energetics, and left atrial indexes
Late after ablation, there was a modest but statisti-
cally significant increase in LVEF from before ablation 
(median, 62% [IQR, 52%–65%] ≤4 weeks before abla-
tion versus 65% [IQR, 59%–68%] at 7 months; n=46; 
P=0.004). However, there was no significant change in 
LVEF from 20 hours to 7 months (P=0.24), and LVEF at 7 
months remained lower than in matched control subjects 
(P<0.001), including when the analysis was restricted to 
patients in SR at 7 months (median, 66% [IQR, 61%–69%] 
versus 71% [IQR, 69%–73%]; P=0.002). Similarly, PSCS 
in patients in SR at 7 months was impaired compared 
with matched control subjects (median, –16% versus 
–18%; P=0.035) with no significant overall improvement 
compared with ≤4 weeks before ablation (P=0.375).
The AF-SR subgroup again showed significant im-
provements in both LVEF and PSCS at 7 months, with no 
changes seen in the other subgroups (Figures 4E and 4F, 
respectively). In the 16 patients who were in AF ≤4 weeks 
before ablation, recovered SR at 20 hours, and remained 
in SR at 7 months, there was a significant improvement 
in LVEF across the 3 visits (median, 55% [IQR, 47%–61%] 
≤4 weeks before ablation, 60% [IQR, 55%–62%] at 20 
hours, and 64% [IQR, 60%–69%] at 7 months; overall 
trend P=0.002; P=0.001 for comparison between ≤4 
weeks before ablation and 7 months; P=0.07 for com-
parison between 20 hours and 7 months).
At 7 months, the AF-SR subgroup showed a significant 
reduction in heart rate, whereas the SR-SR subgroup 
showed a significant increase in heart rate, likely due 
to withdrawal of rate-controlling medications (Figure 4G). 
There was a trend toward an overall increase in cardiac 
output from before ablation (5.9±1.4 L/min at 7 months 
compared with 5.6±1.5 at ≤4 weeks before ablation; 
P=0.054); with no significant differences between sub-
groups (Figure 4H).
When patients were grouped by the presence or 
absence of AF after ablation (rather than by intrascan 
rhythm), the changes in both LVEF and PSCS from ≤4 
weeks before ablation to 7 months were similar between 
groups (median, 2.7% [IQR, –2.3% to 9.7%] in those with 
recurrent AF [n=25] versus 3.3% [IQR, –1.4% to 8.3%] 
in those without recurrent AF [n=21], P=0.83 for LVEF; 
mean –0.2±4% in those with recurrent AF [n=23] versus 
–2.0±5% in those without recurrent AF [n=17], P=0.21 
for PSCS).
Myocardial energetics, as determined by PCr/ATP ra-
tio, was unchanged from ≤4 weeks before ablation to 7 
months (Figure 5A). There were no significant changes in 
PCr/ATP ratio from ≤4 weeks before ablation to 7 months 
in any of the intrascan rhythm subgroups (Figure 5B) or 
A
B
Figure 3. effect of intrascan rhythm on left ventricular 
(lV) ejection fraction (eF) and myocardial energetics in 
patients with atrial fibrillation (aF) before ablation.  
A, Myocardial energetics determined by the ratio of phospho-
creatine to ATP (PCr/ATP) categorized by rhythm during scan 
and, for patients in sinus rhythm (SR), by Holter-determined AF 
burden (higher or lower than median). There is no difference be-
tween the groups (n=10 for SR with lower AF burden, n=11 for 
SR with higher AF burden, and n=28 for AF; P=0.84 by 1-way 
ANOVA). B, LVEF in patients with AF before ablation, similarly 
categorized. Note the significantly lower EF in those in AF com-
pared with those in SR at the time of the scan, regardless of AF 
burden (Kruskal-Wallis P=0.0002). Smaller P values stratified 
by size (**P<0.01, ***P<0.001, ****P<0.0001).
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Figure 4. change in left ventricular (lV) ejection fraction (eF), peak systolic circumferential strain (Pscs), heart 
rate (hr), and cardiac output early and late after ablation, categorized by the intrascan rhythm at each time point.  
One-sample t tests assessed whether changes within each subgroup are significantly different from zero. Changes between 
subgroups were compared by use of 1-way ANOVA; P values for subgroup comparisons are Bonferroni corrected for (Continued )
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between patients with and without AF recurrence after 
ablation (Figure 5C). Overall, energetics remained im-
paired at 7 months compared with matched control sub-
jects (1.78±0.33 versus 2.04±0.29; P=0.001).
Ablation led to a significant reduction in atrial vol-
ume (LAmax, 86±30 mL at 7 months from 102±37 mL 
at ≤4 weeks before ablation; n=46 in paired analysis; 
P<0.001), driven by both the AF-SR and SR-SR sub-
groups (P=0.007 and P<0.001, respectively; online-only 
Data Supplement Figure I). Indeed, at 7 months after ab-
lation, atrial volume in patients with AF was not different 
from that in control subjects (LAmax, 86±30 mL in pa-
tients versus 77±22 mL in control subjects; P=0.202). 
Although LAEF at 7 months improved as expected in 
the AF-SR subgroup (P<0.001; online-only Data Supple-
ment Figure I), there was no significant overall improve-
ment in atrial function postablation (median LAEF, 40% 
[IQR, 27%–47%] at 7 months from 35% [IQR, 17%–49%] 
≤4 weeks before ablation; n=46 in paired analysis; 
P=0.373), and it remained impaired at 7 months com-
pared with control subjects (P<0.001). Similarly, LAEF 
failed to improve even in patients with no recurrent AF 
(median LAEF, 40% [IQR, 32%–48%] at 7 months from 
42% [IQR, 16%–49%] ≤4 weeks before ablation; n=21 
in paired analysis; P=0.230), again remaining impaired 
at 7 months compared with control subjects (P<0.001).
effect of Medications
There were no associations between β-blocker or angio-
tensin-converting enzyme inhibitor/angiotensin II recep-
tor blocker use (online-only Data Supplement Table I) and 
myocardial energetics, LVEF, or PSCS either ≤4 weeks 
before ablation or at 7 months (all P=NS).
DiscussiOn
We undertook a prospective study of patients undergo-
ing first-time ablation of AF, using MR methods to investi-
gate the effect of reducing AF burden on LV function and 
energetics. For the first time, we demonstrate evidence 
of significantly impaired myocardial energetics in the ven-
tricular myocardium of patients with lone AF compared 
with matched control subjects in SR. We also document 
a subtle reduction in LV systolic function in patients with 
AF compared with control subjects, with modest im-
provement (but not normalization) after ablation. Much 
of the improvement in LV function occurs early after the 
procedure, is limited to patients with AF who recover SR 
at the time of the assessment, and thus likely reflects 
changes in hemodynamics at the time of the scan rather 
than true beneficial cardiac remodeling resulting from 
the reduction in AF burden. Indeed, despite a significant 
reduction in AF burden at 7 to 9 months after ablation, 
myocardial energetics does not change and LV function 
does not improve further, remaining impaired compared 
with control subjects in SR. Taken together, these data 
imply that lone AF may be the consequence (rather than 
the cause) of an occult cardiomyopathic process.
lV Function in aF
AF has been implicated as a cause of LV dysfunction 
because previous studies have shown an improvement 
in LV function after catheter ablation12 (including reversal 
of subtle systolic11 and diastolic dysfunction34). Our pa-
tient population had normal LV diastolic function overall, 
although LVEF by cardiac MR was at the lower end of the 
normal range at our institution (Table 2), even after suc-
cessful ablation. There was no evidence of LV dilatation, 
hypertrophy, or concentric remodeling in our patients 
with AF compared with matched control subjects in SR, 
and LGE (indicating LV fibrosis/scar) was an infrequent 
finding in both groups. These results are consistent with 
our intention to focus on patients with lone AF and our 
decision to exclude patients with significant cardiovascu-
lar comorbidity or uncontrolled ventricular rate. Never-
theless, there was clear evidence of reduced LV systolic 
function by both LVEF and PSCS in preablation patients 
compared with matched control subjects, in keeping 
with the results of a previous study with similar inclusion 
criteria.34
The effect of AF ablation on LV function has been in-
vestigated previously, with a recent meta-analysis show-
ing an overall improvement in LVEF of ≈6% (95% CI, 4%–
9%), with the largest improvements seen in patients with 
persistent AF (compared with patients with paroxysmal 
AF) and those with low LVEF (compared with those with 
normal LVEF).12 By using cardiac MR imaging both early 
and late after ablation, our study adds significant further 
Figure 4 continued. multiple comparisons. A, At 20 hours (20H), LVEF improves only in the atrial fibrillation (AF)–sinus rhythm 
(SR) subgroup (P=0.005). B, Similarly, PSCS also improves only in the AF-SR subgroup (denoted by a more negative change; 
P=0.001). C, Only the SR-SR subgroup shows a significant increase in HR early after ablation (P<0.001), and both the AF-SR and 
SR-SR subgroups show a significant increase in cardiac output, without differences between subgroups (D). At 7 months (7M), 
the pattern of change in LV function from ≤4 weeks before ablation (PRE) in subgroups is similar to that at 20 hours, with the 
AF-SR subgroup alone showing significant improvement in LVEF (E; P<0.001) and PSCS (denoted by a more negative change; 
F; P=0.001). G, The changes in HR from ≤4 weeks before ablation in the AF-SR and SR-SR groups are significantly different 
(P<0.0001), and there is a significant difference between the AF-SR and SR-AF groups (P=0.03). H, Similar to 20 hours, there 
are no significant differences between subgroups in the change in cardiac output, with only the SR-SR subgroup demonstrating a 
small increase (P=0.03). Smaller P values stratified by size (**P<0.01, ***P<0.001, ****P<0.0001).
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insight into the effect of AF on LV function. Our results 
indicate that approximately half the overall improvement 
in LVEF observed at 7 months occurs by 20 hours and 
that improvement is restricted to patients who were in 
AF at the scan done ≤4 weeks before ablation and in SR 
at the scans after ablation (rather than those in whom 
ablation caused a significant reduction in AF burden on 
ECG monitoring but who happened to be in SR at the 
time of both scans). Equally important is our finding that 
LV function remains impaired in patients with AF after 
ablation compared with matched control subjects, even 
when considering only those in SR at 7 months and who 
had experienced a significant reduction in AF burden af-
ter the procedure. The modest improvement in LVEF in 
patients recovering SR from AF may reflect the increase 
in LAEF, consistent with recovery of coordinated atrial 
mechanical activity. However, when considering the en-
tire patient cohort, LAEF was unaffected by ablation and 
remained abnormal despite a significant reduction in AF 
burden. This finding is consistent with atrial structural 
and functional remodeling being driven by a process 
independent of the arrhythmia itself (eg, fibrotic atrial 
cardiomyopathy).35,36
Taken together, our data suggest that LV dysfunction 
in patients with paroxysmal or persistent AF reflects the 
combination of adverse hemodynamic effects induced 
acutely by the arrhythmia itself and an underlying cardio-
myopathy. Catheter ablation and restoration of SR can 
improve LV hemodynamics, resulting in modest improve-
ment in LVEF; however, the underlying cardiomyopathy 
persists, and LV function does not completely normalize 
(Figure 6).
Myocardial energetics in aF
Altered cardiac energy metabolism is an early feature 
of cardiomyopathy37 and is prognostically important.38,39 
Very few studies have investigated myocardial energet-
ics in AF. Ex vivo investigations have shown a selective 
reduction in myofibrillar creatine kinase in atrial tissue 
from patients with AF compared with control subjects in 
the absence of changes in total creatine kinase or myo-
sin ATPase activity.40 In goats with pacing-induced AF, 
impaired atrial energetics was detected ex vivo shortly 
after the arrhythmia induction.41 We are not aware of any 
previous in vivo study investigating energetics in the LV 
myocardium in human AF. We used 31P-MRS to noninva-
sively assess myocardial energetics in patients with AF 
A
B
C
Figure 5. Myocardial energetics before and late after 
ablation.  
A, In all patients, there was no change in the ratio of phospho-
creatine to ATP (PCr/ATP) from ≤4 weeks before to (Continued )
Figure 5 continued. 7 months (7M) after ablation (n=42, 
P=0.57, paired t test). There were also no significant differ-
ences in the change in PCr/ATP ratio after ablation in any 
subgroups on the basis of either intrascan rhythm combina-
tions (P=0.37, 1-way ANOVA; B) or the presence or absence 
of recurrent atrial fibrillation (AF) after ablation (P=0.87, 
unpaired t test; C). SR indicates sinus rhythm.
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both before and after ablation. We determined the PCr/
ATP ratio, which is reduced when demand for ATP out-
weighs ATP synthesis (as in ischemia) or with reduction 
in the total creatine pool (as occurs in heart failure).17 
Our finding of a significantly lower LV PCr/ATP ratio in 
patients with AF than in control subjects supports the no-
tion of an underlying cardiomyopathy, particularly in the 
context of the demonstrated subtle LV dysfunction. It is 
important to note that the findings that energetics is not 
affected by heart rhythm at the time of assessment and 
does not improve after successful AF ablation suggest 
that the cardiomyopathic process may be “upstream” of 
AF (Figure 6). This is befitting the idea that underlying 
atrial disease may actually precede and promote lone 
AF, as suggested by a number of recent studies.42–44
The reduction in PCr/ATP ratio in patients with AF 
compared with matched control subjects is relatively 
subtle, which may reflect the relative insensitivity of this 
measure to the true degree of underlying energetic dys-
function compared with other 31P-MRS parameters such 
as the rate of ATP production (the creatine kinase flux) 
or the creatine kinase forward rate constant, kf.
45 Future 
studies should determine the rate of creatine kinase flux 
in patients with AF because this parameter may reflect 
both the underlying cardiomyopathy and the response to 
treatment more accurately than the PCr/ATP ratio.38,46
clinical implications and Future Directions
Our results support the notion that lone AF is the con-
sequence of an occult cardiomyopathy that persists 
despite restoration of SR. This raises the intriguing pos-
sibility that such a process (which may develop with ag-
ing and exposure to risk factors) may also contribute to 
recurrence of AF after ablation. However, future studies 
are needed to examine whether therapeutic strategies 
that target the adverse cardiometabolic phenotype re-
duce AF recurrence and improve outcomes. In line with 
this paradigm, our findings may add mechanistic insight 
to recent clinical trial data showing that weight loss and 
intensive risk factor management can dramatically re-
duce AF burden, symptoms, and adverse cardiac remod-
eling47 and improve AF-free survival after ablation.48
We also show that the improvement in LVEF after ab-
lation may not reflect beneficial LV remodeling induced 
by SR. The results of studies appropriately powered to 
determine the effects of ablation on hard end points are 
awaited, and our findings suggest that, at least in lone 
AF, caution is needed when interpreting improvement 
in LVEF as a biomarker of possible prognostic benefit 
from ablation. Further studies are needed to determine 
whether 31P-MRS assessment of myocardial energetics 
(PCr/ATP or creatine kinase flux) could play an important 
role in this regard.
limitations
AF presents technical challenges to quantitative cardiac 
MR imaging because of the irregularity of the RR interval. 
As described in Methods, we have used a number of 
techniques to counter these issues. In addition, images 
were analyzed in a blinded fashion and in randomized 
order to reduce the risk of systematic bias. Although 
we have not corroborated the quantitative assessments 
in this study against invasive measures, previous work 
has shown that MR assessment of volumes and EF is 
accurate in AF and correlates well with catheterization 
measurements.49
Our study design cannot exclude that 6 to 9 months 
is too soon for full recovery of ventricular function or en-
ergetics after successful ablation; nevertheless, this is 
a reasonable time point for medium-term follow-up, and 
failure of normalization by this time is clinically relevant. 
It is also possible (but in our opinion less likely) that a 
short duration of lone AF can cause irreversible damage 
to the ventricular myocardium, with the extent of damage 
A B
Figure 6. Proposed schematic representation of the relationships between lone atrial fibrillation (aF), subtle left 
ventricular (lV) dysfunction, and upstream cardiomyopathy and the effect of ablation.  
A, Lone AF and subtle LV dysfunction may be tissue-specific manifestations of an upstream occult cardiomyopathy, character-
ized by impaired energetics. AF further contributes to LV dysfunction via adverse hemodynamics. B, Successful catheter ablation 
restores sinus rhythm and/or reduces AF burden and leads to a modest increase in LV function via improvement in hemodynam-
ics. However, the underlying cardiomyopathy remains, and myocardial energetics and LV function do not normalize.
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unrelated to cumulative AF burden. This hypothesis could 
be tested in future population-based, large-scale imaging 
studies that include rhythm-monitoring investigations.
Last, we studied a specific group of patients with lone 
AF. Further studies are needed to establish whether our 
findings are applicable to other AF patient populations.
conclusions
Patients with lone AF show impaired LV function and 
myocardial energetics compared with matched control 
subjects in SR, and these parameters do not normalize 
despite a significant reduction in AF burden after suc-
cessful ablation. These findings imply that AF may be the 
consequence (rather than the cause) of an underlying 
cardiomyopathy. Comprehensive therapeutic strategies 
to target and reverse the adverse cardiometabolic phe-
notype may be needed to reduce AF recurrence and to 
improve outcomes.
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